Your First Hot Covid-19 Takeover Stock

Dear Fellow Investor,

Big Pharma loves to buy small biotech's right after the market drops.

When the market dropped 19% in the fourth quarter of 2018, Ex-Wall Street CEO Dylan Jovine picked 3 biotech stocks ripe for a takeover.

On October 1st, 2018, he recommended Tesaro... 63 days later it was taken over for an easy 91% profit...

On October 19, 2018 he recommended Pacific Biosciences... 4 days later it was taken over for a quick 72% gain...

On January 4, 2019 he recommended Loxo Oncology... 3 days later it was taken over for a fast 71% gain...

Well guess what? The Coronavirus market drop has given Big Pharma its first takeover target of 2020.

In this special letter, you'll learn why Dylan thinks now is the best time to make money with this tiny stock.

You'll discover:

• Why Big Pharma firms Allergan, Celgene and others have invested over $1 billion into this tiny biotech.
• Why President Trump thinks this biotech's breakthrough is a matter of national security.
• How a takeover could make you $41,250 in profits any day now.

That's because in this letter, we'll show you how get into this company right now - before it's too late!

You don't want to miss this.

Read this urgent letter now >>>

Sincerely,

Brad Sullivan
Publisher
Behind the Markets

---

The above is a paid advertisement. StockEarnings.com is not affiliated with nor does it endorse any trading system, newsletter or other similar service. StockEarnings.com does not assure or verify any performance claims made by such systems, newsletters or services. Trading involves a significant and substantial risk of loss and may not be suitable for everyone. You should only trade with money you can afford to lose. There is no assurance that you will gain from your trading activity and it is possible that you may lose all of, or if trading on margin more than, your investment. Some of the results shown may be based on simulated performance. SIMULATED OR HYPOTHETICAL PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE THE RESULTS SHOWN IN AN ACTUAL PERFORMANCE RECORD, SUCH RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, BECAUSE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MY HAVE UNDER OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED OR HYPOTHETICAL PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE GAINS OR LOSSES SIMILAR TO THOSE SHOWN.

Past performance is not necessarily indicative of future performance. This brief statement cannot disclose all the risks and other significant aspects of trading. You should carefully study trading and consider whether such activity is suitable for you in light of your circumstances and financial resources before you trade.
This message is considered by regulation to be a commercial and advertising message. This is a permission-based message. You are receiving this email either because you opted-in to this subscription or because you have a prior existing relationship with StockEarnings.com or one of its subsidiaries, and previously provided your email address to us. This email fully complies with all laws and regulations. If you do not wish to receive this email, then we apologize for the inconvenience. You can immediately discontinue receiving this email by clicking on the unsubscribe or profile link and you will no longer receive this email. We will immediately redress any complaints you may have. If you have any questions, please send an email with your questions to info@stocksearning.com.

If you would no longer like to receive StockEarnings partners and advertisers emails, you can click here to unsubscribe.